Literature DB >> 22008772

Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.

E V Kurbatova1, V M Gammino, J Bayona, M Becerra, M Danilovitz, D Falzon, I Gelmanova, S Keshavjee, V Leimane, C D Mitnick, M I D Quelapio, V Riekstina, A Taylor, P Viiklepp, M Zignol, J P Cegielski.   

Abstract

Monthly culture is usually recommended to monitor treatment of multidrug-resistant tuberculosis (MDR-TB). As mycobacterial laboratory capacity is limited in many settings, TB programs need evidence to decide whether monthly cultures are necessary compared to other approaches. We simulated three alternative monitoring strategies (culture every 2 or 3 months, and monthly smears alone) in a cohort of MDR-TB patients in Estonia, Latvia, Philippines, Russia and Peru from 2000 to 2004. This retrospective analysis illustrated that less frequent testing delays confirmation of bacteriological conversion. This would prolong intensive treatment, hospitalization and respiratory isolation, increasing cost and toxicity. After conversion, less frequent testing could delay diagnosis of possible treatment failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008772     DOI: 10.5588/ijtld.11.0101

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  How many sputum culture results do we need to monitor multidrug-resistant-tuberculosis (MDR-TB) patients during treatment?

Authors:  Saskia Janssen; Xavier Padanilam; Rianna Louw; Russel Mahanyele; Gerrit Coetzee; Thomas Hänscheid; Tjalling Leenstra; Martin P Grobusch
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

2.  Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program.

Authors:  Yatin N Dholakia; Divya P Shah
Journal:  Lung India       Date:  2013-10

3.  Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment.

Authors:  Dylan B Tierney; Molly F Franke; Mercedes C Becerra; Félix A Alcántara Virú; César A Bonilla; Epifanio Sánchez; Dalia Guerra; Maribel Muñoz; Karim Llaro; Eda Palacios; Lorena Mestanza; Rocío M Hurtado; Jennifer J Furin; Sonya Shin; Carole D Mitnick
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

4.  Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Authors:  Carole D Mitnick; Richard A White; Chunling Lu; Carly A Rodriguez; Jaime Bayona; Mercedes C Becerra; Marcos Burgos; Rosella Centis; Theodore Cohen; Helen Cox; Lia D'Ambrosio; Manfred Danilovitz; Dennis Falzon; Irina Y Gelmanova; Maria T Gler; Jennifer A Grinsdale; Timothy H Holtz; Salmaan Keshavjee; Vaira Leimane; Dick Menzies; Giovanni Battista Migliori; Meredith B Milstein; Sergey P Mishustin; Marcello Pagano; Maria I Quelapio; Karen Shean; Sonya S Shin; Arielle W Tolman; Martha L van der Walt; Armand Van Deun; Piret Viiklepp
Journal:  Eur Respir J       Date:  2016-09-01       Impact factor: 16.671

5.  Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience.

Authors:  Abhijeet Singh; Rajendra Prasad; Ram Awadh Singh Kushwaha; Rahul Srivastava; Belur Hosmane Giridhar; Viswesvaran Balasubramanian; Amita Jain
Journal:  Lung India       Date:  2019 Sep-Oct

6.  Challenges and controversies in defining totally drug-resistant tuberculosis.

Authors:  Peter Cegielski; Paul Nunn; Ekaterina V Kurbatova; Karin Weyer; Tracy L Dalton; Douglas F Wares; Michael F Iademarco; Kenneth G Castro; Mario Raviglione
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.